Structural and Functional Changes of Myocardium Under Conditions of Postinfarcate
Cardiosclerosis, Arterial Hypertension, Type 2 Diabetes Mellitus
NO Kravchun1*, IP Dunaieva2, IA Ilchenko2, PP Kravchun3 and IV Cherniavskaia4
1Multidisciplinary Medical Center “Life Park”, Kharkiv, Ukraine
2Kharkiv National Medical University of the Ministry of Health of Ukraine, Kharkiv, Ukraine
3IQVIA RDS, Kyiv, Ukraine
4Medical Center “REFIT”, Kharkiv, Ukraine
*Corresponding Author: NO Kravchun, Multidisciplinary Medical Center “Life Park”, Kharkiv, Ukraine.
October 07, 2021; Published: November 23, 2021
The article evaluates the structural and functional changes of the myocardium in patients with postinfarction cardiosclerosis, hypertension and type 2 diabetes depending on the systolic function of the left ventricle and the functional class of chronic heart failure. A study of 68 patients with postinfarction cardiosclerosis, hypertension and type 2 diabetes mellitus was performed. The comparison group included 60 patients with postinfarction cardiosclerosis, the control group - 30 almost healthy individuals. Type 2 diabetes mellitus is a potentiator of left ventricular myocardial remodeling in patients with systolic dysfunction caused by postinfarction cardiosclerosis. Comorbidity of postinfarction cardiosclerosis, arterial hypertension and type 2 diabetes mellitus leads to the progression of postinfarction remodeling.
Keywords: Postinfarction Cardiosclerosis; Type 2 Diabetes Mellitus; Chronic Heart Failure; Systolic Dysfunction
- V Ormazabal., et al. “Association between insulin resistance and the development of cardiovascular disease”. Cardiovascular Diabetology 17 (2018): 122.
- Petrie JR., et al. “Diabetes, Hypertension, and cardiovascular disease: Clinical Insights and Vascular Mechanisms”. Canadian Journal of Cardiology 5 (2018): 575-584.
- Zhou MS., et al. “Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease”. Vascular Medicine 5 (2012): 330-341.
- B Williams., et al. “ESC/ESH Guidelines for the management of arterial hypertension”. European Heart Journal 33 (2018): 3021-3104.
- Serhiyenko V and Serhiyenko O. “Diabetes mellitus and arterial hypertension”. International journal of endocrinology (Ukraine) 2 (2021): 175-188.
- G Lastra., et al. “Type 2 diabetes mellitus and hypertension: an update”. Endocrinology and Metabolism Clinics of North America 1 (2014): 103-122.
- Savoia C and Touyz RM. “Hypertension, Diabetes Mellitus, and Excess Cardiovascular Risk: Importance of Baseline Systolic Blood Pressure”. Hypertension5 (2017): 882-883.
- Gorbunova O., et al. “The level of protection from oxidative stress and three-year dynamics of structural and functional changes of the myocardium in chronic ischemic heart disease in men”. Georgian Medical News 285 (2018): 63-69.
- M Fudim., et al. “The Prognostic Value of Diastolic and Systolic Mechanical Left Ventricular Dyssynchrony Among Patients with Coronary Heart Disease”. JACC Cardiovascular Imaging7 (2019): 1215-1226.
- Y Lin., et al. “Effect of Trimetazidine on Diabetic Patients with Coronary Heart Diseases: A Meta-Analysis of Randomized, Controlled Trials”. Chinese Medical Sciences Journal3 (2020): 226-238.
- Chen Y., et al. “Blood glucose fluctuations in patients with coronary heart disease and diabetes mellitus correlates with heart rate variability: A retrospective analysis of 210 cases”. Nigerian Journal of Clinical Practice9 (2020): 1194-1200.
- SJ Shah., et al. “Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF”. European Heart Journal37 (2018): 3439-3450.
- Zhou D., et al. “Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study”. Scientific Reports1 (2018): 9418.
- Frangogiannis NG and Kovacic JC. “Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar”. Journal of the American College of Cardiology17 (2020): 2219-2235.
- Verbovoy AF., et al. “Diabetic macroangiopathy”. Therapeutic archive 10 (2019): 139-143.
- AF Verbovoy., et al. “Modern approaches to management of cardiovascular risk factors at patients with diabetes mellitus type 2”. Therapeutic archive 8 (2018): 113-117.
- NR Poulter., et al. “Are the American Heart Association/American College of Cardiology High Blood Pressure Guidelines Fit for Global Purpose? Thoughts From the International Society of Hypertension”. Hypertension2 (2018): 260-262.
- B Williams., et al. “2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension”. Journal of Hypertension33 (2018): 3021-3104.
- T Unger., et al. “2020 International Society of Hypertension Global Hypertension Practice Guidelines”. Hypertension6 (2020): 1334-1357.
- Green JB. “Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox”. Postgraduate Medical3 (2014): 190-204.
- M Guglin., et al. “Heart failure as a risk factor for diabetes mellitus”. Cardiology2 (2014): 84-92.
- H Ohuchi., et al. “Low fasting plasma glucose level predicts morbidity and mortality in symptomatic adults with congenital heart disease”. International Journal of Cardiology2 (2014): 306-312.
- C Varas-Lorenzo., et al. “The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and metaanalysis of published observational studies”. BMC Cardiovascular Disorders1 (2014): 129.